FDA approves use of Novavax COVID-19 vaccine

FDA approves use of Novavax COVID-19 vaccine
# 14 July 2022 01:42 (UTC +04:00)

The United States Food and Drugs Administration authorized on Wednesday the emergency use of a COVID-19 vaccine developed by Novavax Inc. to support preventing severe disease symptoms in adult Americans, APA reports citing Teletrader.

"Today's authorization offers adults in the US who have not yet received a COVID-19 vaccine another option that meets the FDA's rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization," FDA Commissioner Robert Califf noted.

Novavax's vaccine is administered in two doses three weeks apart and is considered to be around 90.4% effective in preventing COVID-19 symptoms in the adult population and 78.6% among the elderly.

#
#

THE OPERATION IS BEING PERFORMED